TCF7L2 rs4905166: Genetic Context and Health Insights
The rs4905166 single-nucleotide polymorphism is a noncoding genomic variant located within the TCF7L2 gene locus on human chromosome 10. While the broader TCF7L2 region is famously recognized as one of the most significant genomic areas linked to pancreatic beta-cell function and type 2 diabetes risk, evidence specifically linking rs4905166 itself to health traits remains limited. Learning your rs4905166 genotype provides interesting population genetics context but does not serve as a diagnostic indicator of metabolic disease.
What each genotype means
Typical glucose regulation
You carry two copies of the common G allele at rs4905166 in the TCF7L2 locus. Research indicates that this genotype reflects the baseline population profile for glucose homeostasis and is not associated with elevated genetic susceptibility to type 2 diabetes. However, complex traits like metabolic regulation are governed by many lifestyle factors and genetic markers throughout the genome.
Found in approximately 50% to 55% of individuals of European ancestry and is the predominant genotype across most global populations.
Modestly altered glucose susceptibility
You carry one copy of the A minor allele and one copy of the G allele at rs4905166. While the broader TCF7L2 locus is strongly tied to pancreatic beta-cell function and insulin secretion, direct clinical evidence specifically isolated to rs4905166 remains limited and largely reflects linkage with other known regional variants. Carrying this genotype may confer a subtle statistical difference in metabolic trait profiles, but it does not diagnose any condition.
Carried by approximately 40% of individuals of European ancestry, with lower frequencies observed in East Asian populations.
Altered glucose susceptibility
You carry two copies of the A minor allele at rs4905166 within the TCF7L2 gene region. In population-level research, variations across the TCF7L2 locus have been correlated with altered glucose regulation and type 2 diabetes susceptibility, although direct independent functional evidence for this specific variant remains limited. This statistical association does not predict disease onset, and routine metabolic health practices remain the primary drivers of individual outcomes.
Observed in roughly 7% to 8% of individuals of European ancestry and is relatively uncommon worldwide.
Genomic Location and the TCF7L2 Locus
The single-nucleotide polymorphism rs4905166 resides on chromosome 10 within the intronic structure of the TCF7L2 (transcription factor 7-like 2) gene. Like the majority of common variants identified in human genome-wide scans, rs4905166 does not alter a protein-coding sequence directly. Instead, it sits in a vast noncoding region that spans several linkage disequilibrium blocks. In human genetics, linkage disequilibrium describes how alleles located physically close together on a chromosome tend to be inherited in blocks across generations. Because of this architecture, noncoding SNPs often serve as genomic landmarks or tags for neighboring regulatory regions rather than causing functional cellular changes on their own. The TCF7L2 locus harbors multiple independent and semi-correlated signals that influence chromatin structure, enhancer looping, and adjacent gene transcription across metabolic tissues, placing rs4905166 squarely inside one of the most extensively studied regulatory regions in modern human metabolic genomics.
Biological Role of the TCF7L2 Gene
The TCF7L2 gene encodes a high-mobility group box-containing transcription factor that plays a fundamental role in the canonical Wnt signaling pathway. This signaling cascade coordinates cell proliferation, differentiation, and tissue homeostasis throughout the body. In the context of metabolic biology, TCF7L2 is expressed in pancreatic islet beta cells, adipose tissue, the liver, and the intestinal tract. Within pancreatic islets, TCF7L2-driven transcription orchestrates the cellular machinery required for glucose sensing, proinsulin processing, and the exocytosis of insulin in response to nutrient stimulation. It also participates in the incretin pathway, modulating how the gut hormone GLP-1 stimulates insulin release after meals. Experimental models demonstrate that altering TCF7L2 expression alters beta-cell survival and impairs insulin secretion. However, the precise way individual noncoding variants modulate this transcription factor's expression across human tissues remains an area of ongoing scientific investigation.
Evaluating the Clinical and Research Evidence
While landmark TCF7L2 single-nucleotide polymorphisms such as rs7903146 and rs12255372 exhibit strong, highly replicated associations with impaired insulin secretion and type 2 diabetes risk, the research evidence specifically evaluating rs4905166 is cataloged as limited. Large-scale genome-wide association studies (GWAS) routinely interrogate hundreds of thousands of variants across the TCF7L2 locus, but rs4905166 is primarily observed in cataloged associations through linkage disequilibrium with other regional signals rather than demonstrating independent causal liability. Statistical associations in complex trait genetics reflect population-level correlations, not direct individual destinies or clinical diagnoses. Because current functional and epidemiological studies have not firmly established rs4905166 as a driver of glycemic dysregulation or pharmacological outcomes independently of better-characterized lead variants, caution is warranted when interpreting this specific marker in commercial genetic reports.
How Common Is rs4905166 Across Populations?
The frequency of rs4905166 alleles varies markedly depending on geographic and ancestral background, reflecting human evolutionary history and genetic drift. In European ancestral cohorts, the minor allele frequency is approximately 0.28, meaning roughly 28% of surveyed chromosomes carry the alternative allele. Across broader global populations cataloged in reference resources like gnomAD and the 1000 Genomes Project, allele distributions within the TCF7L2 locus often exhibit substantial population divergence. For instance, haplotype frequencies across this genomic locus diverge significantly between West African, East Asian, and European reference panels. Because the underlying linkage disequilibrium patterns differ between ancestral groups, an association observed between a tag variant and a trait in one population may not translate equally to individuals of different ancestral backgrounds, emphasizing the importance of diverse cohorts in genetic research.
What You Can and Cannot Do With This Information
Discovering your rs4905166 genotype through consumer genetic testing can offer an engaging window into your personal genome, but it is essential to understand the boundaries of this information. This variant is not a medical test, cannot diagnose prediabetes or type 2 diabetes, and cannot predict your personal health trajectory. Complex metabolic conditions develop through intricate interactions between hundreds of small-effect genetic variants, dietary patterns, physical activity, sleep quality, and environmental factors. Knowing your status at rs4905166 does not warrant changes to medical treatment or prescribed medications. If you have questions regarding blood sugar management, personal risk factors, or family history of diabetes, consult a qualified healthcare provider. Similarly, any decisions regarding metabolic medications or clinical screening intervals should always be evaluated in partnership with a physician.
How common is this variant?
The minor allele at rs4905166 has a frequency of approximately 0.28 in populations of European ancestry, with variant distributions across the broader TCF7L2 locus showing notable divergence among global ancestral groups.
Frequently asked questions
Does having a variant in TCF7L2 mean I will get diabetes?
No. Genetic variants in TCF7L2 only reflect small statistical associations across large study populations, not absolute outcomes. Type 2 diabetes is a multifactorial condition shaped heavily by lifestyle, nutrition, age, and broad polygenic background.
Can rs4905166 tell me which diabetes medications to take?
No. While some variants in TCF7L2 have been researched for potential modest influences on sulfonylurea responsiveness, rs4905166 has no established clinical pharmacogenomic utility. You should never adjust, start, or stop any medication without direct guidance from your doctor or pharmacist.
Why is the evidence for rs4905166 categorized as limited?
Although the TCF7L2 gene is widely recognized in diabetes research, most landmark findings point to distinct index variants like rs7903146. rs4905166 lacks strong, independent replication demonstrating a direct functional or clinical consequence on its own.
How does rs4905166 differ from rs7903146?
Both variants reside in the TCF7L2 genomic region on chromosome 10, but rs7903146 is the primary lead variant extensively studied for its impact on beta-cell function and diabetes susceptibility. rs4905166 is an adjacent marker that is inherited alongside other regional variants in certain haplotypes.
Sources & further reading
Educational information only, last refreshed 9/9/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4905166?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29